Abstract
Amid controversial reports that COVID-19 can be treated with a combination of the antimalarial drug hydroxychloroquine (HCQ) and the antibiotic azithromycin (AZI), a clinical trial (ONCOCOVID, NCT04341207 ) was launched at Gustave Roussy Cancer Campus to investigate the utility of this combination therapy in cancer patients. In this preclinical study, we investigated whether the combination of HCQ+AZI would be compatible with the therapeutic induction of anticancer immune responses. For this, we used doses of HCQ and AZI that affect whole-body physiology (as indicated by a partial blockade in cardiac and hepatic autophagic flux for HCQ and a reduction in body weight for AZI), showing that their combined administration did not interfere with tumor growth control induced by the immunogenic cell death inducer oxaliplatin. Moreover, the HCQ+AZI combination did not affect the capacity of a curative regimen (cisplatin + crizotinib + PD-1 blockade) to eradicate established orthotopic lung cancers in mice. In conclusion, it appears that HCQ+AZI does not interfere with the therapeutic induction of therapeutic anticancer immune responses.
Keywords: COVID-19; SARS-CoV-2; cancer; hydroxychloroquine; immune checkpoint; immunotherapy.
【저자키워드】 COVID-19, SARS-CoV-2, Hydroxychloroquine, Immunotherapy, Cancer, breath, immune checkpoint, 【초록키워드】 Tumor, clinical trial, Azithromycin, Hydroxychloroquine, Immunotherapy, body weight, combination therapy, lung cancer, antimalarial, immune, PD-1, mice, cancers, immune responses, therapeutic, Cancer patients, HCQ, utility, preclinical study, antibiotic, Combination, administration, dose, Campus, regimen, antimalarial drug, tumor growth, crizotinib, cisplatin, oxaliplatin, autophagic flux, blockade, doses, anticancer, inducer, Affect, indicated, investigated, treated, appear, interfere, not affect, reduction in, AZI, curative, Gustave Roussy, immunogenic cell death, 【제목키워드】 Treatment, immune response, Azithromycin, Hydroxychloroquine, therapeutic, anticancer,